What is the recommended management for opioid‑induced hyperalgesia?

Management of Opioid-Induced Hyperalgesia

The primary management strategy for opioid-induced hyperalgesia (OIH) is opioid rotation (switching to a different opioid) combined with dose reduction, as this allows titration to adequate analgesia without the same disabling effects caused by toxic metabolite accumulation. 1, 2, 3

Core Management Algorithm

Step 1: Recognize OIH

Look for these specific clinical features that distinguish OIH from tolerance:

• Paradoxical increase in pain despite escalating opioid doses
• Diffuse pain extending beyond the original pain site
• Allodynia (pain from normally non-painful stimuli) on physical examination
• Pain that worsens with opioid dose increases rather than improves

Step 2: Immediate Interventions

Primary Strategy - Opioid Rotation:

• Switch to an alternative opioid agonist (e.g., from morphine to methadone, oxycodone, hydromorphone, or fentanyl) 1, 2, 3
• Reduce the equianalgesic dose by 25-50% when rotating to account for incomplete cross-tolerance
• This approach is particularly effective because different opioids produce different toxic metabolites, and switching eliminates the accumulated metabolites causing CNS toxicity 1, 2

Alternative Route:

• Consider changing the administration route (e.g., from oral to transdermal or parenteral) as this may allow adequate analgesia without the same side effects 1, 2

Step 3: Add Multimodal Analgesia

Reduce opioid requirements by adding:

• NMDA antagonists: Ketamine at subanaesthetic doses has specific evidence for intractable pain and OIH 2, 4, 5
• NSAIDs or COX-2 inhibitors 6
• Neuropathic pain agents: Pregabalin or gabapentinoids for neuropathic components 7, 8
• Regional anesthesia/nerve blocks when anatomically appropriate 1, 9

Step 4: Consider Opioid Dose Reduction

If opioid rotation alone is insufficient:

• Gradually taper the opioid dose while maintaining multimodal analgesia 1, 2
• In some patients, dose tapering or discontinuation paradoxically ameliorates pain rather than worsening it 6
• The goal is to break the cycle where increasing doses exacerbate hyperalgesia

Step 5: Specialized Interventions for Refractory Cases

For cancer pain patients with OIH:

• Consider radiotherapy for bone metastases or neural compression causing pain 1, 9
• Evaluate for spinal (epidural/intrathecal) opioid administration with local anesthetics or clonidine, which may reduce systemic opioid requirements 10
• Refer for invasive anaesthetic or neurosurgical treatments if pain remains inadequately controlled 2

For patients on medications for opioid use disorder (MOUD):

• Continue methadone or buprenorphine - do not discontinue baseline therapy 11
• Add short-acting full opioid agonists titrated to effect for acute pain on top of maintenance therapy 11
• For buprenorphine patients specifically: either divide daily dose to every 6-8 hours for analgesic effect, or temporarily convert to methadone 30-40 mg/day which binds less tightly to μ-receptors 11

Critical Pitfalls to Avoid

1. Do not simply escalate the same opioid - this worsens OIH rather than improving it 6
2. Do not confuse OIH with tolerance - tolerance requires more drug for the same effect; OIH causes increased pain sensitivity with more drug 6
3. Do not abruptly discontinue opioids without tapering, as this risks severe withdrawal 11
4. Do not use meperidine - it has poor efficacy, multiple drug interactions, and active metabolites that accumulate, particularly problematic in renal insufficiency 12

Symptomatic Management of Associated CNS Toxicity

While addressing OIH, manage concurrent opioid-related CNS symptoms:

• Myoclonic jerks: Opioid rotation is the primary treatment 1, 2
• Confusion/hallucinations: Major tranquilizers 1, 9
• Drowsiness: Psychostimulants (methylphenidate 5-10 mg 1-3 times daily, limited to morning/early afternoon) 7, 3

Evidence Quality Note

The strongest guideline evidence consistently identifies opioid rotation as first-line management 1, 2, 3. While newer research explores ketamine 4, 5 and lidocaine infusions 4, these remain adjunctive strategies. The 2011-2012 ESMO guidelines provide the most explicit algorithmic approach, emphasizing that CNS toxicity symptoms like OIH specifically respond to switching opioids due to toxic metabolite accumulation 1, 2.